Comparative costs of treatment with epoetin alfa and darbepoetin alfa for anemia in the oncology and nephrology settings

References

• Adams PE, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat.10, 1–203 (1999).
   Google Scholar
• World Health Organization. WHO Essential Medicines Library – EMLib: Iron deficiency anemia. World Health Organization (2004).
   Google Scholar
• Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl Cancer Inst.91, 1616–1634 (1999).
   PubMed Web of Science ®Google Scholar
• Harrison L, Shasha D, Shiaova L, White C, Ramdeen B, Portenoy R. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin. Oncol.28(Suppl.), 54–59 (2001).
   PubMed Web of Science ®Google Scholar
• Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin. Oncol.25(Suppl.), 43–46 (1998).
   PubMed Web of Science ®Google Scholar
• Sobrero A, Puglisi F, Guglielmi A et al. Fatigue: a main component of anemia symptomatology. Semin. Oncol.28(2 Suppl. 8), 15–18 (2001).
   PubMed Web of Science ®Google Scholar
• Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer91(12), 2214–2221 (2001).
   PubMed Web of Science ®Google Scholar
• Nissenson AR, Wade S, Goodnough LT, Knigth K, Dubois RW. Economic burden of anemia in an insured population. J. Manag Care Pharm.11(7), 565–574 (2005).
   PubMedGoogle Scholar
• McClellan WM, Aronoff SL, Bolton WK et al. The prevalence of anemia in patients with chronic kidney disease. Curr. Med. Res. Opin.20(9), 1501–1510 (2004).
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am. J. Kidney Dis.37(1 Suppl. 1), S182–S238 Erratum in: Am. J. Kidney Dis.2038(2002), 2442 (2001).
   PubMed Web of Science ®Google Scholar
• Couture F, Turner AR, Melosky B et al. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management. Oncologist10(1), 63–71 (2005).
   PubMed Web of Science ®Google Scholar
• Brand A. Immunological aspects of blood transfusions. Transpl. Immunol.10(2–3), 183–190 (2002).
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Parrish RS et al. Influence of allogeneic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervix. Gynecol. Obstet. Invest.56(1), 28–34 (2003).
   PubMed Web of Science ®Google Scholar
• Dellinger EP, Anaya DA. Infectious and immunologic consequences of blood transfusion. Crit. Care8(Suppl. 2), S18–S23 (2004).
   Google Scholar
• Bohlius J, Wilson J, Seidenfeld J et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst. Rev. 3:CD003407 (2006).
   Google Scholar
• Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J. Clin. Oncol.20(19), 4083–4107 (2002).
   PubMed Web of Science ®Google Scholar
• Prescribing Information for Procrit® (epoetin alfa). Ortho Biotech Products. Raritan, NJ, November (2005).
   Google Scholar
• Prescribing Information for Aranesp® (darbepoetin alfa). Amgen Inc. Thousand Oaks, CA, December (2005).
   Google Scholar
• Macdougall IC, Gray SJ, Elston O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J. Am. Soc. Nephrol.10(11), 2392–2395 (1999).
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Yee LK, Senecal FM et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist9, 696–707 (2004).
   PubMed Web of Science ®Google Scholar
• Glaspy J, Vadhan-Raj S, Patel R et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J. Clin. Oncol.24(15), 2290–2297 (2006).
   PubMed Web of Science ®Google Scholar
• Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist10(8), 642–650 (2005).
   PubMed Web of Science ®Google Scholar
• Reed SD, Radeva JI, Daniel DB, Fastenau JM, Williams D, Schulman KA. Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia. Curr. Med. Res. Opin.21(10), 1527–1533 (2005).
   PubMed Web of Science ®Google Scholar
• Campos SM, Duh MS, Lefebvre P, Rosberg J. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J. Natl Compr. Canc. Netw.3(6), 807–816 (2005).
   PubMedGoogle Scholar
• Rearden TP, Charu V, Saidman B et al. Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA). J. Clin. Oncol.22(Suppl.), 8064 (2004).
   Google Scholar
• Straus DJ, Testa MA, Sarokhan BJ et al. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer107(8), 1909–1917 (2006).
   PubMed Web of Science ®Google Scholar
• Steensma DP. Management of anemia in patients with cancer. Curr. Oncol. Rep.6(4), 297–304 (2004).
   PubMedGoogle Scholar
• Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl J. Med.27(339), 584–590 (1998).
   Google Scholar
• Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer104, 2822–2829 (2005).
   PubMed Web of Science ®Google Scholar
• Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia. Curr. Med. Res. Opin.21(10), 1677–1682 (2005).
   PubMed Web of Science ®Google Scholar
• Duh MS, Mark TL. Cost–effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia. Expert Rev. Pharmacoeconomics Outcomes Res.5(4), 383–394 (2005).
   PubMedGoogle Scholar
• Barosi G, Marchetti M, Liberato NL. Cost–effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br. J. Cancer78(6), 781–787 (1998).
   PubMed Web of Science ®Google Scholar
• Fagnoni P, Limat S, Chaigneau L et al. Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer. Support Care Cancer14(10), 1030–1037 (2006).
   PubMedGoogle Scholar
• Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB. Cost effectiveness, quality- adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics16, 459–472 (1999).
   PubMed Web of Science ®Google Scholar
• Morreale A, Plowman B, DeLattre M, Boggie D, Schaefer M. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr. Med. Res. Opin.20(3), 381–395 (2004).
   PubMed Web of Science ®Google Scholar
• Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS. Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of four observational studies. Clin. Ther.28(10), 1701–1709 (2006).
   PubMedGoogle Scholar
• Bolge SC, Fastenau JM, Howell JB, Piech CT, Donohue JA. Dosing patterns of erythropoietic agents and their association with provider visits in patiens with cancer and anemia. Blood104(11) (2004) (Abstract 5306).
   Google Scholar
• Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Tak Piech C, Duh MS. Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. Curr. Med. Res. Opin.22(9), 1623–1631 (2006).
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Mody SH, McKenzie RS. Real-world dosing of erythropoietic agents in a nationwide sample of patients with cancer receiving chemotherapy: results from a large retrospective, observational study. Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 11th Annual Meeting, Philadelphia, PA, USA, May 20–24 (2006).
   Google Scholar
• Harris HM, del Aguila M, Lopez JM, McKenzie RS, Piech CT. Anemia treatment costs in cancer patients treated with epoetin alfa or darbepoetin alfa in a managed-care population. Presented at: Academy of Managed Care Pharmacy (AMCP) 2005 Educational Conference, Nashville, TN, USA, October 5–8 (2005).
   Google Scholar
• Barron JJ, Mody SH, Boudreaux MY, Yang W, Groesbeck JM, McKenzie RS. Dosing distribution patterns and associated costs of erythropoietic agents in anemic patients with cancer receiving chemotherapy. Presented at: 40th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting, Las Vegas, NV, USA, December 4–8 (2005).
   Google Scholar
• Memisoglu A, Peake C, Buscaino E, Forlenza JB, Neary M, McKenzie RS. Outcomes and costs in epoetin alfa (EPO) and darbepoetin alfa (DARB) treated cancer patients: Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (D.O.S.E.) registry. Presented at: Multinational Association of Supportive Care in Cancer (MASCC) 18th International Symposium, Toronto, Canada, June 22–24 (2006).
   Google Scholar
• Grad O, Davis J, Vichare R et al. Dosing and outcomes study of erythropoiesis-stimulating therapies (D.O.S.E.). Support Care Cancer12(419) (2004).
   Google Scholar
• Reed SD, Radeva JI, Daniel DB et al. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia. Evidence from a 16-week randomised trial. Pharmacoeconomics24(5), 479–494 (2006).
   PubMed Web of Science ®Google Scholar
• Duh MS, Vekeman F, McKenzie RS et al. Comparison of epoetin alfa and darbepoetin alfa treatment costs in an inpatient oncology setting. Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Philadelphia, PA, May 20–24 (2006).
   Google Scholar
• Smith J, Mahoney A, P, Watson S, Mody SH, McKenzie RS. Hospital inpatient utilization of epoetin alfa (EPO) and darbepoetin alfa (DARB) in patients with cancer and pre-dialysis chronic kidney disease (pCKD). Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 11th Annual International Meeting, Philadelphia, PA, USA, May 20–24 (2006).
   Google Scholar
• Killian AD, Gupta V, Goetz AE. Cost analysis of erythropoietic-stimulating therapy dosing in hospitalized oncology patients. Ann. Pharmacother.40(3), 421–426 (2006).
   PubMedGoogle Scholar
• Sikand H, Greco T, Watson SH, Decter A, Mody SH, Piech CT. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen for oncology patients. Presented at: American Society of Health-System Pharmacists (ASHP) 39th Midyear Clinical Meeting, Orlando, FL, December 5–9 (2004).
   Google Scholar
• Kruep EJ, Basskin LE. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting. Am. J. Health Syst. Pharm.62, 2597–2603 (2005).
   PubMed Web of Science ®Google Scholar
• Locatelli F, Olivares J, Walker R et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int.60(2), 741–747 (2001).
   PubMed Web of Science ®Google Scholar
• Nissenson AR, Swan SK, Lindberg JS et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am. J. Kidney Dis.40(1), 110–118 (2002).
   PubMed Web of Science ®Google Scholar
• Vanrenterghem Y, Barany P, Mann JF et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int.62(6), 2167–2175 (2002).
   PubMed Web of Science ®Google Scholar
• Toto RD, Pichette V, Navarro J et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am. J. Nephrol.24(4), 453–460 (2004).
   PubMed Web of Science ®Google Scholar
• Provenzano R, Bhaduri S, Singh A, PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin. Nephrol.64(2), 113–123 (2005).
   PubMed Web of Science ®Google Scholar
• Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin. Nephrol.63(5), 327–334 (2005).
   PubMed Web of Science ®Google Scholar
• Papatheofanis FJ, McKenzie RS, Mody SH, Suruki RY, Piech CT. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. Curr. Med. Res. Opin.22(5), 837–842 (2006).
   PubMed Web of Science ®Google Scholar
• Decter A, Mody SH, Little J, Duh MS, Watson S, Fastenau J. A cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen. Presented at: Annual Meeting of the American College of Clinical Pharmacy (ACCP), October 24–27, Dallas, TX, USA (2004).
   Google Scholar
• Papatheofanis FJ, McKenzie RS, Mody SH, Seybold P, Piech CT. Hematologic outcomes and dosing patterns of erythropoietic agents in anemic predialysis kidney disease (pCKD) patients from an observational study. Presented at: American Society of Nephrology (ASN) 38th Annual Renal Week Meeting, Philadelphia, PA, USA, November 8–13 (2005).
   Google Scholar
• McLaughlin T, Mody SH, McKenzie RS, Bookhart B. Dosing patterns and associated costs of erythropoietic agents in a nationwide sample of anemic patients with pre-dialysis chronic kidney disease. Presented at: Academy of Managed Care Pharmacy 18th Annual Meeting, Seattle, WA, USA, April 5–8 (2006).
   Google Scholar
• Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Piech CT. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. Clin. Ther.28(9), 1443–1450 (2006).
   PubMed Web of Science ®Google Scholar
• Barron JJ, Mody SH, Boudreaux MY, Yang W, Groesbeck JM, McKenzie RS. Dosing distribution patterns and associated costs of erythropoietic agents in patients with pre-dialysis chronic kidney disease from three large managed care organizations. Presented at: American Society of Nephrology (ASN) 38th Annual Renal Week Meeting, Philadelphia, PA, USA, November 8–13 (2005).
   Google Scholar
• Mody SH, McKenzie RS, Bookhart B. Epoetin alfa and darbepoetin alfa dosing patterns in pre-dialysis chronic kidney disease. Presented at: International Society for Pharmacoeconomics and Outcomes Research 11th Annual international Meeting, Philadelphia, PA, USA, May 20–24 (2006).
   Google Scholar
• Persson U, Borg S, Jansson S et al. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response. Adv. Ther.22(3), 208–224 (2005).
   PubMed Web of Science ®Google Scholar
• Reichardt B. Cost comparison of epoetin alfa, epoetin β and darbepoetin alfa for cancer patients with anaemia in the clinical practice setting. J. Clin. Pharm. Ther.31, 503–512 (2006).
   PubMedGoogle Scholar
• Cremieux P, Vekeman F, Lefebvre P. Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application. J. Oncol. Pharm. Pract.12(3), 165–178 (2006).
   PubMedGoogle Scholar